Skip navigation
Home
Browse
Communities
& Collections
Browse Items by:
Issue Date
Author
Title
Advisor
Help
Sign on to:
My DSpace
Receive email
updates
Edit Profile
Adelaide Research & Scholarship
Adelaide Research & Scholarship
Search
Search:
All collections
Schools and Disciplines
School of Medicine
Medicine
Medicine publications
for
Current filters:
Title
Author
Subject
Date Issued
Advisor
School
Department
Organisation
Equals
Contains
ID
Not Equals
Not Contains
Not ID
Title
Author
Subject
Date Issued
Advisor
School
Department
Organisation
Equals
Contains
ID
Not Equals
Not Contains
Not ID
Title
Author
Subject
Date Issued
Advisor
School
Department
Organisation
Equals
Contains
ID
Not Equals
Not Contains
Not ID
Title
Author
Subject
Date Issued
Advisor
School
Department
Organisation
Equals
Contains
ID
Not Equals
Not Contains
Not ID
Start a new search
Add filters:
Use filters to refine the search results.
Title
Author
Subject
Date Issued
Advisor
School
Department
Organisation
Equals
Contains
ID
Not Equals
Not Contains
Not ID
Results 1-10 of 12 (Search time: 0.006 seconds).
previous
1
2
next
Item hits:
Preview
Issue Date
Title
Author(s)
2010
Mutation analysis of BCR-ABL tyrosine kinase domain in new chronic phase-chronic myeloid leukemia patients with suboptimal response or treatment failure from imatinib treatment
Kim, D.
;
Kim, D.
;
Kim, S.
;
Goh, H.
;
Pane, F.
;
Hughes, T.
;
Radich, J.
;
Lin, P.
;
Saglio, G.
;
Branford, S.
;
Martinelli, G.
;
Soverini, S.
;
Hochhaus, A.
;
American Society of Hematology Meeting (52nd : 2010 : Florida, CA.)
2014
Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib
Hughes, T.
;
Saglio, G.
;
Kantarjian, H.
;
Guilhot, F.
;
Niederwieser, D.
;
Rosti, G.
;
Nakaseko, C.
;
De Souza, C.
;
Kalaycio, M.
;
Meier, S.
;
Fan, X.
;
Menssen, H.
;
Larson, R.
;
Hochhaus, A.
2014
Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice daily
Hughes, T.
;
Hochhaus, A.
;
Kantarjian, H.
;
Cervantes, F.
;
Guilhot, F.
;
Niederwieser, D.
;
Le Coutre, P.
;
Rosti, G.
;
Ossenkoppele, G.
;
Lobo, C.
;
Shibayama, H.
;
Fan, X.
;
Menssen, H.
;
Kemp, C.
;
Larson, R.
;
Saglio, G.
2013
Rapid initial decline in BCR-ABL1 is associated with superior responses to second-line nilotinib in patients with chronic-phase chronic myeloid leukemia
Stein, A.
;
Martinelli, G.
;
Hughes, T.
;
Muller, M.
;
Beppu, L.
;
Gottardi, E.
;
Branford, S.
;
Soverini, S.
;
Woodman, R.
;
Hochhaus, A.
;
Kim, D.
;
Saglio, G.
;
Radich, J.
2012
Concurrent use of proton pump inhibitors or H2 blockers did not adversely affect nilotinib efficacy in patients with chronic myeloid leukemia
Yin, O.
;
Giles, F.
;
Baccarani, M.
;
le Coutre, P.
;
Chiparus, O.
;
Gallagher, N.
;
Saglio, G.
;
Hughes, T.
;
Hochhaus, A.
;
Kantarjian, H.
;
Larson, R.
2013
Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase
Hochhaus, A.
;
Saglio, G.
;
Larson, R.
;
Kim, D.
;
Etienne, G.
;
Rosti, G.
;
De Souza, C.
;
Kurokawa, M.
;
Kalaycio, M.
;
Hoenekopp, A.
;
Fan, X.
;
Shou, Y.
;
Kantarjian, H.
;
Hughes, T.
2015
BCR-ABL1 mutation development during first-line treatment with dasatinib or imatinib for chronic myeloid leukemia in chronic phase
Hughes, T.
;
Saglio, G.
;
Quintás-Cardama, A.
;
Mauro, M.
;
Kim, D.
;
Lipton, J.
;
Bradley-Garelik, M.
;
Ukropec, J.
;
Hochhaus, A.
2012
Population pharmacokinetic and exposure-response analysis of nilotinib in patients with newly diagnosed Ph plus chronic myeloid leukemia in chronic phase
Larson, R.
;
Yin, O.
;
Hochhaus, A.
;
Saglio, G.
;
Clark, R.
;
Nakamae, H.
;
Gallagher, N.
;
Demirhan, E.
;
Hughes, T.
;
Kantarjian, H.
;
le Coutre, P.
2012
Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up
Larson, R.
;
Hochhaus, A.
;
Hughes, T.
;
Clark, R.
;
Etienne, G.
;
Kim, D.
;
Flinn, I.
;
Kurokawa, M.
;
Moiraghi, B.
;
Yu, R.
;
Blakesley, R.
;
Gallagher, N.
;
Saglio, G.
;
Kantarjian, H.
2011
Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial
Kantarjian, H.
;
Hochhaus, A.
;
Saglio, G.
;
de Souza, C.
;
Flinn, I.
;
Stenke, L.
;
Goh, Y.
;
Rosti, G.
;
Nakamae, H.
;
Gallagher, N.
;
Hoenekopp, A.
;
Blakesley, R.
;
Larson, R.
;
Hughes, T.
Discover
Author
9
Kantarjian, H.
9
Larson, R.
7
Kim, D.
6
Gallagher, N.
4
le Coutre, P.
4
Rosti, G.
3
Blakesley, R.
3
Clark, R.
3
Etienne, G.
3
Fan, X.
.
next >
Subject
6
Antineoplastic Agents
6
Benzamides
6
Piperazines
6
Pyrimidines
5
Humans
5
Imatinib Mesylate
4
Fusion Proteins, bcr-abl
4
Leukemia, Myeloid, Chronic-Phase
4
Protein Kinase Inhibitors
3
Chronic myeloid leukemia
.
next >
Date issued
1
2015
2
2014
2
2013
3
2012
2
2011
2
2010